NEUMORA THERAPEUTICS INC (NMRA)
Health Care · Clinical-stage biopharmaceutical / neuropsychiatric therapeutics · NASDAQ
Neumora is a precision neuroscience company using data-driven drug discovery to develop novel therapies for brain and centrally mediated diseases.
What NEUMORA THERAPEUTICS INC does
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for brain and centrally mediated neuropsychiatric disorders. The company employs a precision neuroscience approach that integrates biomarker discovery, patient stratification, and data-driven methods to improve drug development efficiency. Neumora aims to advance multiple product candidates through clinical trials while establishing collaborations and partnerships to support commercialization and scaling of its pipeline.
Themes: ["Precision neuroscience / targeted CNS therapeutics"]
Fundamentals
- Price$1.65 as of 2026-07-09 close
- Market cap$295M as of 2026-07-10
- 1-year return+76.3% as of 2026-07-09 close
- ROE-181.7% as of 2026-07-10
- Debt / equity0.75 as of 2026-07-10
- Beta2.86 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial execution risk: ability to demonstrate safety and efficacy of product candidates and successful completion of clinical studies is uncertain and may impact regulatory approval timelines."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.